Back
Galectin Faces Securities Probe After FDA Drug Update
Back
Stock News
Themes
Galectin Faces Securities Probe After FDA Drug Update
Galectin Faces Securities Probe After FDA Drug Update
Edgen Stock
·
Jan 19 2026, 05:56
Share to
Share to
Copy link
GALT
-0.72%
source:
[1] Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud
Recommend
Apple Stock Climbs as Investors Shun Big Tech's $650B AI Spending
Feb 18 2026, 00:32
Similarweb Swings to Profit, Beating Q4 Estimates
Feb 17 2026, 23:58
Hormel Sells Turkey Business, Reaffirms 2026 Guidance
Feb 17 2026, 23:57
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Jan 19 2026, 05:56Edgen Stock·Jan 19 2026, 05:56
Edgen Stock·Jan 19 2026, 05:56